机构:[1]Jiangsu Key Laboratory of Translational Research and Therapy for Neuropsychiatric Diseases and College of Pharmaceutical Sciences, Soochow University, Suzhou, Jiangsu, China[2]College of Pharmaceutical Sciences and the Collaborative Innovation Center for Brain Science, Soochow University, Suzhou, China[3]Department of neurosurgery, Brain Hospital affiliated to Nanjing medical University, Nanjing, China[4]Department of Neurosurgery, the Second Affiliated Hospital of Soochow University, Suzhou, China
Chemoresistance remains a major challenge for the treatment of glioma. In this study, weinvestigated the role of Clock 1 (Clk1), which encodes an enzyme that is necessary for ubiquinone biosynthesis in glioma chemoresistance in vitro. The results showed that Clk1 was highly expressed in GL261 mouse glioma cells which were most sensitive to 1,3Bis (2-chloroethyl) 1 nitrosourea (BCNU) while was low expressed inBCNUresistant cells such as glioma cancer stem cells, T98G, U87MGand U251 glioma cells. Knockdown of Clk1 in GL261 glioma cells significantly reduced BCNU-or cisplatin-induced cell apoptosis, whereas the proliferative activity and the expression of multidrug resistance-related genes including MDR1, O6-methylguanine- DNA methyltransferase, and GSTP1 were not changed. When Clk1 was re-expressed in Clk1 knockdown GL261 glioma cells, the BCNU sensitivity was restored. The mechanistic study revealed that knockdown of Clk1 in GL261 glioma cells increased aerobic glycolysis including high glucose consumption, lactate production, and up-regulation of glycolysis- associated genes. Inhibition of glycolysis can reverse the chemoresistance elicited by Clk1 knockdown in GL261 cells. Moreover, knockdown of Clk1 induced HIF-1 alpha expression in GL261 glioma cells which was found to be mediated by AMPactivated protein kinase (AMPK)/mechanistic target of rapamycin (mTOR) signaling pathway. Both metformin and rapamycin reversed the chemoresistance of Clk1 knockdown GL261 glioma cells. Over-expression of Clk1 significantly increased the sensitivity of T98G or U251 human glioblastoma cells to BCNU which was accompanied by decreased lactate secretion, decreased expression of HIF-1 alpha, AMPK activation, and inhibition of mTOR pathway. Inhibition of glycolysis or activation of AMPK did not alter Clk1 expression in variant glioma cell lines suggesting that aerobic glycolysis is not an upstream event of Clk1 expression in glioma cells. Taken together, our results revealed, for the first time, that mitochondrial Clk1 regulated chemoresistance in glioma cells through AMPK/mTOR/HIF-1 alpha mediated glycolysis pathway.
基金:
This work was supported by funds from the National Science
Foundation of China (81372688, 81130023, 81373382) and the
National Basic Research Plan (973) of the Ministry of Science and
Technology of China (2011CB504403). Support provided from the
Priority Academic Program Development of Jiangsu Higher Education
Institutes (PAPD) and the Jiangsu Key Laboratory Grant (BM2013003)
is also appreciated. The authors declare no competing interest.
第一作者机构:[1]Jiangsu Key Laboratory of Translational Research and Therapy for Neuropsychiatric Diseases and College of Pharmaceutical Sciences, Soochow University, Suzhou, Jiangsu, China[2]College of Pharmaceutical Sciences and the Collaborative Innovation Center for Brain Science, Soochow University, Suzhou, China
共同第一作者:
通讯作者:
通讯机构:[*1]Key Laboratory of Translational Research and Therapy for Neuropsychiatric Diseases and College of Pharmaceutical Sciences, Soochow University, Suzhou, Jiangsu 215021, China
推荐引用方式(GB/T 7714):
Zhang Li,Yang Huicui,Zhang Wenbin,et al.Clk1-regulated aerobic glycolsis is involved in glioma chemoresistance[J].JOURNAL OF NEUROCHEMISTRY.2017,142(4):574-588.doi:10.1111/jnc.14096.
APA:
Zhang, Li,Yang, Huicui,Zhang, Wenbin,Liang, Zhongqin,Huang, Qiang...&Zheng, Long Tai.(2017).Clk1-regulated aerobic glycolsis is involved in glioma chemoresistance.JOURNAL OF NEUROCHEMISTRY,142,(4)
MLA:
Zhang, Li,et al."Clk1-regulated aerobic glycolsis is involved in glioma chemoresistance".JOURNAL OF NEUROCHEMISTRY 142..4(2017):574-588